Literature DB >> 23571646

[Pemphigus vulgaris. Therapy with cyclophosphamide].

L Vanstreels1, A Alkhateeb, M Megahed.   

Abstract

Pemphigus vulgaris is an autoimmune blistering disorder. The diagnosis is based on clinical presentation, histology, and direct and indirect immunofluorescence. Optimal treatment remains the greatest challenge. Treatment options include combinations of systemic steroids with azathioprine, mycophenolate, and cyclophosphamide. However, there is little solid data regarding the drug of choice. In our patient, the best tolerated and effective treatment was found after several therapeutic attempts.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23571646     DOI： 10.1007/s00105-013-2553-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  7 in total

1.  Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.

Authors:  Cheyda Chams-Davatchi; Nafiseh Esmaili; Maryam Daneshpazhooh; Mahin Valikhani; Kamran Balighi; Zahra Hallaji; Masoumeh Barzegari; Maryam Akhyani; S Zahra Ghodsi; Hassan Seirafi; Mohammad-Javad Tabrizi Nazemi; Hossein Mortazavi; Mostafa Mirshams-Shahshahani
Journal:  J Am Acad Dermatol       Date:  2007-06-21       Impact factor: 11.527

2.  Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases.

Authors:  Detlef Zillikens; Kurt Derfler; Rüdiger Eming; Gerhard Fierlbeck; Matthias Goebeler; Michael Hertl; Silke C Hofmann; Franz Karlhofer; Ocko Kautz; Martin Nitschke; Andreas Opitz; Sven Quist; Christian Rose; Stefan Schanz; Enno Schmidt; Iakov Shimanovich; Michael Michael; Fabian Ziller
Journal:  J Dtsch Dermatol Ges       Date:  2007-10       Impact factor: 5.584

Review 3.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

Review 4.  The adjuvant therapy of pemphigus. An update.

Authors:  J C Bystryn; N M Steinman
Journal:  Arch Dermatol       Date:  1996-02

Review 5.  A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus.

Authors:  Linda K Martin; Victoria P Werth; Elmer V Villaneuva; Dédée F Murrell
Journal:  J Am Acad Dermatol       Date:  2011-02-25       Impact factor: 11.527

6.  Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.

Authors:  Michael Hertl; Detlef Zillikens; Luca Borradori; Leena Bruckner-Tuderman; Harald Burckhard; Rüdiger Eming; Andreas Engert; Matthias Goebeler; Silke Hofmann; Nicolas Hunzelmann; Franz Karlhofer; Ocko Kautz; Undine Lippert; Andrea Niedermeier; Martin Nitschke; Martin Pfütze; Marcel Reiser; Christian Rose; Enno Schmidt; Iakov Shimanovich; Michael Sticherling; Sonja Wolff-Franke
Journal:  J Dtsch Dermatol Ges       Date:  2008-01-14       Impact factor: 5.584

7.  Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus.

Authors:  Deborah L Cummins; Daniel Mimouni; Grant J Anhalt; Carlos H Nousari
Journal:  J Am Acad Dermatol       Date:  2003-08       Impact factor: 11.527
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.